

**Form 51-102F3
Material Change Report**

**Section 7.1 of National Instrument 51-102
Continuous Disclosure Obligations**

Item 1 Name and Address of Company

1933 Industries Inc.
Suite 300 – 1055 W. Hastings Street
Vancouver, BC, V6E 2E9

Item 2 Dates of Material Change

November 9, 2020

Item 3 News Release

A news release relating to the material change was disseminated by CISION on November 5, 2020. The news release has also been filed on the System for Electronic Document Analysis and Retrieval (“SEDAR”) and is available at www.sedar.com.

Item 4 Summary of Material Change

1933 Industries Inc. (the “Company” or “1933 Industries”) announced that it has signed a Membership Interest Purchase Definitive Agreement.

Item 5 Full Description of Material Change

1933 Industries Inc. (the “Company” or “1933 Industries”) announced that it has signed a Membership Interest Purchase Definitive Agreement (the “Agreement”) among the Company, its subsidiary FN Pharmaceuticals, E. Mark Zobrist and Linmark Enterprises Corp., to purchase the remaining 9% interest in AMA Production LLC thereby resulting in the Company’s 100% ownership of the subsidiary which contains the property located at 5035 Geist Ave., Las Vegas, Nevada.

Subject to the terms of the Agreement, in consideration of the acquisition of the remaining 9%, the Company will issue, in the aggregate, 3,700,000 non-transferable share purchase warrants, exercisable at a price of \$0.075 per share expiring on June 13, 2024. The warrants, and any shares exercised pursuant to the warrants, will be subject to a four month and one day hold period as required by applicable securities laws in Canada and such additional restrictions as may be applicable pursuant to U.S. securities laws.

As part of the transaction, a total of 1,650,000 outstanding warrants and 2,050,000 options will be cancelled, and the operating agreement for Alternative Medicine Association LC (“AMA”) will be amended to concede complete managerial control of AMA to the Company.

The Agreement is subject to the regulatory approvals, including the approval of the Canadian Securities Exchange, as applicable. The closing date is expected to take place on or around November 6, 2020.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not Applicable.

Item 8 Executive Officer

To reach an executive officer, please contact:

Alexia Helgason, VP, IR and Corporate Communications
604-674-4756 (ext. 1)

Item 9 Date of Report

November 13, 2020.